Blog
NAD+ and Alzheimers Disease: A Multi-Pathway Approach to Neuroprotection
GLP1 receptor agonists (GLP1RAs), approved for metabolic conditions such...
GLP1 and DPP4 Compounds: Emerging Areas of Investigation in Neurological Pain Models
Recent scientific literature has explored how glucagon-like peptide-1 receptor...
GLP1 Receptor Agonists: Investigational Insights into Addiction-Related Models
Substance use disorders, including alcohol, nicotine, opioid, and stimulant...
GLP1 Receptor Agonists: Investigational Agents in Liver Fat Reduction and NASH Progression Models
Non-alcoholic fatty liver disease (NAFLD) is among the most...
Intermittent Fasting and Breast Cancer: A Review of Emerging Research in Treatment Tolerability
As survivorship increases among individuals with a history of...
Can GLP-1 Receptor Agonists Influence Tumor Biology? A Preclinical Research Overview
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally designed for...
BPC‑157: The Healing Peptide with Multi-System Benefits
BPC157, short for Body Protection Compound 157, is a...
Selank: The Peptide for Calm, Clarity, and Cognitive Support
Selank is a synthetic peptide developed at the Institute...
Understanding the Differences Between GLP1 and GLP2: A Guide to the Glucagon-Like Peptide
The glucagon-like peptide (GLP) family consists of peptide hormones...
GLP1 and Lipids: A New Frontier in Cholesterol and Triglyceride Management
Glucagon-like peptide1 receptor agonists (GLP1 RAs) have gained widespread...
